Ali Health (00241)'s revenue for the 2024 fiscal year ending the end of March this year exceeded the 5% year-on-year increase forecast at the end of March.
The Zhitong Finance App learned that Citi released a research report stating that it gave Ali Health (00241) a “buy” rating, with a target price of HK$8. The company's revenue for the 2024 fiscal year ended the end of March this year increased 1% year on year to 27 billion yuan, exceeding the 5% year-on-year increase forecast by the company at the end of March. Net profit increased 65% to 883 million yuan, which is also higher than the company's original forecast of a 30% year-on-year increase. Gross margin increased to 21.8% from 21.3% in FY2023.